Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00006364 · ClinicalTrials.gov registry record · Phase 2

Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia

A Phase 2 study of Chronic Myelogenous Leukemia, BCR-ABL1 Positive and Chronic Phase Chronic Myelogenous Leukemia, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 2
Development phase
50
Enrollment target
1
Study location

NCT00006364 is a Phase 2 study of Chronic Myelogenous Leukemia, BCR-ABL1 Positive and Chronic Phase Chronic Myelogenous Leukemia that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 50 participants, above the 42-participant average among 10 other Chronic Myelogenous Leukemia, BCR-ABL1 Positive trials with a reported enrollment target (19% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00006364, a Phase 2 study of Chronic Myelogenous Leukemia, BCR-ABL1 Positive and Chronic Phase Chronic Myelogenous Leukemia, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 2
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

Phase II trial to study the effectiveness of homoharringtonine in treating patients who have chronic phase chronic myelogenous leukemia. Drugs used in chemotherapy, such as homoharringtonine, work in different ways to stop cancer cells from dividing so they stop growing or die

Conditions Studied

Chronic Myelogenous Leukemia, BCR-ABL1 Positive Chronic Phase Chronic Myelogenous Leukemia Childhood Chronic Myelogenous Leukemia Relapsing Chronic Myelogenous Leukemia

Interventions

  • OTHER laboratory biomarker analysis
  • OTHER pharmacological study
  • DRUG omacetaxine mepesuccinate

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 1999-11
Phase Phase 2

Sponsor

National Cancer Institute (NCI)

3,257 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00006364

The ClinicalTrials.gov registry entry for NCT00006364 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 42-participant average among 10 other Chronic Myelogenous Leukemia, BCR-ABL1 Positive trials with a reported enrollment target (19% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Chronic Myelogenous Leukemia, BCR-ABL1 Positive appearing as the primary indexed condition, and to 3 interventions - of which laboratory biomarker analysis is the first listed.

NCT00006364 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT00006364 about?

NCT00006364 is a clinical study titled "Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia". Phase II trial to study the effectiveness of homoharringtonine in treating patients who have chronic phase chronic myelogenous leukemia. Drugs used in chemotherapy, such as homoharringtonine, work in different ways to stop cancer cells from dividing so they stop growing or die

What is the current status of trial NCT00006364?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 1999-11.

What conditions does trial NCT00006364 study?

This clinical trial studies the following conditions: Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia, Childhood Chronic Myelogenous Leukemia, Relapsing Chronic Myelogenous Leukemia.

What interventions are being tested in trial NCT00006364?

The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), omacetaxine mepesuccinate (DRUG).

Who is sponsoring clinical trial NCT00006364?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00006364 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Myelogenous Leukemia, BCR-ABL1 Positive

All registered trials for this condition

Chronic Phase Chronic Myelogenous Leukemia

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.